| Cover - USD ($) | 12 Months Ended | | |
| Dec. 31, 2021 | Apr. 25, 2022 | Jun. 30, 2021 |
| Cover [Abstract] | | | |
| Document Type | 10-K/A | | |
| Document Annual Report | true | | |
| Document Period End Date | Dec. 31,
2021 | | |
| Document Transition Report | false | | |
| Entity File Number | 001-39695 | | |
| Entity Registrant Name | VIATRIS INC. | | |
| Entity Incorporation, State or Country Code | DE | | |
| Entity Tax Identification Number | 83-4364296 | | |
| Entity Address, Address Line One | 1000 Mylan Boulevard | | |
| Entity Address, City or Town | Canonsburg | | |
| Entity Address, State or Province | PA | | |
| Entity Address, Postal Zip Code | 15317 | | |
| City Area Code | (724) | | |
| Local Phone Number | 514-1800 | | |
| Title of 12(b) Security | Common Stock, par value $0.01 per share | | |
| Trading Symbol | VTRS | | |
| Security Exchange Name | NASDAQ | | |
| Entity Well-known Seasoned Issuer | Yes | | |
| Entity Voluntary Filers | No | | |
| Entity Current Reporting Status | Yes | | |
| Entity Interactive Data Current | Yes | | |
| Entity Filer Category | Large Accelerated Filer | | |
| Entity Small Business | false | | |
| Entity Emerging Growth Company | false | | |
| ICFR Auditor Attestation Flag | true | | |
| Entity Shell Company | false | | |
| Common Stock, Par or Stated Value Per Share | $ 0.01 | | |
| Entity Common Stock, Shares Outstanding | | 1,212,301,241 | |
| Entity Public Float | | | $ 17,237,737,213 |
| Documents Incorporated by Reference | None. | | |
| Entity Central Index Key | 0001792044 | | |
| Amendment Flag | true | | |
| Amendment Description | This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, originally filed on February 28, 2022 (the “Original Filing”). We are filing this Amendment to include the information required by Part III and not included in the Original Filing, as we do not intend to file a definitive proxy statement for an annual meeting of shareholders within 120 days of the end of our fiscal year ended December 31, 2021. In addition, in connection with the filing of this Amendment and pursuant to the rules of the Securities and Exchange Commission (the “SEC”), we are including with this Amendment new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Item 15 of Part IV has also been amended to reflect the filing of these new certifications. Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing. As used in this Amendment, unless the context requires otherwise, the “Company,” “Viatris,” “our,” and “we” mean Viatris Inc. and its consolidated subsidiaries, “NASDAQ” means The NASDAQ Global Select Stock Market, and “U.S. GAAP” means accounting principles generally accepted in the United States (“U.S.”). On November 16, 2020, Viatris, formerly known as Upjohn Inc., Mylan N.V. (“Mylan”) and Pfizer Inc. (“Pfizer”) consummated the combination of Mylan with Pfizer’s Upjohn business (the “Upjohn Business”) through a Reverse Morris Trust transaction. In accordance with the terms and conditions of the Business Combination Agreement, dated as of July 29, 2019, as amended from time to time, among Viatris, Mylan, Pfizer and certain of their affiliates (the “Business Combination Agreement”) and the Separation and Distribution Agreement between Viatris and Pfizer, dated as of July 29, 2019, as amended from time to time, (1) Pfizer contributed the Upjohn Business to Viatris, so that the Upjohn Business was separated from the remainder of Pfizer’s businesses (the “Separation”), (2) following the Separation, Pfizer distributed, on a pro rata basis (based on the number of shares of Pfizer common stock held by holders of Pfizer common stock as of the record date of November 13, 2020 (the “Record Date”)), all of the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the Record Date (the “Distribution”), and (3) immediately following the Distribution, Viatris and Mylan engaged in a strategic business combination transaction (the “Combination”). As a result of the Combination, Viatris holds the combined Upjohn Business and Mylan business. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter. | | |
| Document Fiscal Year Focus | 2021 | | |
| Document Fiscal Period Focus | FY | | |
| Current Fiscal Year End Date | --12-31 | | |
